The LuViva® Advanced Cervical Scan was chosen as best designed new medical device of 2014 at the 17th Annual Medical Device Excellence Awards (MDEA) ceremony held Wednesday, June 11, 2014, in conjunction with the MD&M East event at the Jacob K. Javits Convention Center in New York. LuViva, a newly introduced product for the early detection of disease that leads to cervical cancer, is manufactured and sold by Guided Therapeutics, Inc. (OTCBB:GTHP) (OTCQB:GTHP).

LuViva was chosen as the Gold Medal Winner in the Hospital Devices and Therapeutic Products’ category by a panel of independent experts due to excellence in product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery.

“Receiving this award is a validation of the design and engineering effort that went into creating LuViva,” said Gene Cartwright Chief Executive Officer of Guided Therapeutics. “Not only is LuViva very user-friendly to operate, but it communicates the strength of its underlying technology to the patient and healthcare professional. We want to thank our design team at Big Bang and our key suppliers, Seaway Plastics, Gupta Permold and Herman Miller for their ongoing support.”

About the Medical Device Excellence Awards

The MDEA competition is the MedTech Industry's Premier Awards Program. Since its inception in 1998, the mission of the MDEA has been to recognize significant advances in medical product design and engineering that improve the quality of healthcare delivery and accessibility. Designed to focus attention upon the complexity of product development and to showcase examples of what can be achieved when it is well done, the MDEA celebrates the achievements of medical product manufacturers, their suppliers, and the many people behind the scenes — engineers, scientists, designers, and clinicians — who are responsible for the groundbreaking products that are saving lives, improving patient healthcare, and changing the face of MedTech. For a complete list of winners, click here.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics is also developing a non-invasive test for the early detection of esophageal cancer using the technology platform. For more information, visit:

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2012, and subsequent quarterly reports.


Guided Therapeutics, Inc.
Bill Wells, 770-242-8723
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469